R S McIntyre

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1615-28. 2007
  2. ncbi A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:697-706. 2012
  3. ncbi The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Behav Brain Res 237:164-71. 2013
  4. ncbi A review of published evidence reporting on the efficacy and pharmacology of lurasidone
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada
    Expert Opin Pharmacother 13:1653-9. 2012
  5. ncbi Efficacy of antimanic treatments in mixed states
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:22-36. 2012
  6. ncbi Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:163-9. 2012
  7. ncbi The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:69-81. 2012
  8. ncbi Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Clin Schizophr Relat Psychoses 5:217-20. 2012
  9. ncbi Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 68:1352-7. 2007
  10. ncbi Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial
    Roger S McIntyre
    University of Toronto, Toronto, ON, Canada M5T 2S8
    J Affect Disord 122:27-38. 2010

Collaborators

Detail Information

Publications94

  1. ncbi Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1615-28. 2007
    ..Extant data provide the basis for formulating a hypothesis that TZDs may be salutary for cognitive deficits and several aspects of somatic health (e.g., cardiovascular disease) associated with mood disorders...
  2. ncbi A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:697-706. 2012
    ..In keeping with this view, we tested the hypothesis that intranasal insulin administration would improve measures of neurocognitive performance in euthymic adults with bipolar disorder...
  3. ncbi The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Behav Brain Res 237:164-71. 2013
    ..Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue...
  4. ncbi A review of published evidence reporting on the efficacy and pharmacology of lurasidone
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada
    Expert Opin Pharmacother 13:1653-9. 2012
    ..Moreover, lurasidone's efficacy in bipolar depression is awaited to determine whether this agent can be considered as a treatment alternative for depressive symptoms in adults with bipolar disorder...
  5. ncbi Efficacy of antimanic treatments in mixed states
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:22-36. 2012
    ..To review the efficacy of pharmacological agents in bipolar mixed states...
  6. ncbi Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:163-9. 2012
    ..Treating comorbid conditions in patients with mood disorders requires sufficient decision support to inform appropriate treatment...
  7. ncbi The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:69-81. 2012
    ..Our group conducted a comprehensive literature review to provide evidence-based recommendations for treating metabolic comorbidity in individuals with major depressive disorder (MDD) and bipolar disorder (BD)...
  8. ncbi Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Clin Schizophr Relat Psychoses 5:217-20. 2012
    ..This article briefly reviews the efficacy, as well as safety and tolerability, data pertaining to asenapine in bipolar mania and schizophrenia. Postulated mechanism of action is also reviewed...
  9. ncbi Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 68:1352-7. 2007
    ..This investigation was undertaken to explore the relationship between alcohol/illicit drug dependence and overweight/obesity in individuals with bipolar I disorder...
  10. ncbi Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial
    Roger S McIntyre
    University of Toronto, Toronto, ON, Canada M5T 2S8
    J Affect Disord 122:27-38. 2010
    ..This randomized, double-blind, placebo-controlled trial assessed the efficacy, safety, and tolerability of asenapine in bipolar I disorder...
  11. ncbi Maintenance treatment in bipolar disorder: a focus on aripiprazole
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Department of Pharmacology, Toronto, ON, Canada
    Expert Rev Neurother 7:919-25. 2007
    ..This article provides a succinct review of treatments approved by the US FDA for maintenance in bipolar disorders, with a focus on the most recently approved atypical antipsychotic, aripiprazole...
  12. ncbi Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Curr Diab Rep 9:51-9. 2009
    ..This article discusses the rate of co-occurrence and the points of pathophysiologic commonality between the metabolic syndrome and major depressive disorder...
  13. ncbi Measuring depressive symptoms in the naturalistic primary-care setting
    R S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Int J Clin Pract 61:1278-82. 2007
    ..A quantifiable critical objective in the management of depression is to achieve and sustain full symptomatic remission. The HAMD-7 is a depression metric validated in both tertiary and primary-care settings...
  14. ncbi Aripiprazole for the maintenance treatment of bipolar I disorder: A review
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Canada
    Clin Ther 32:S32-8. 2010
    ..Few pharmacologic agents have been approved by the US Food and Drug Administration for the maintenance treatment of bipolar disorder...
  15. ncbi A preclinical and clinical rationale for quetiapine in mood syndromes
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1211-9. 2007
    ..The in vitro pharmacodynamic profile of quetiapine is predictive of antidepressant activity in mood syndromes. Available clinical evidence has established quetiapine as an effective monotherapy in bipolar depression...
  16. ncbi Medical comorbidity in bipolar disorder: re-prioritizing unmet needs
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:406-16. 2007
    ..The aim of this review is to synthesize results from extant investigations which report on the co-occurrence of bipolar disorder and medical comorbidity...
  17. ncbi Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Rev Neurother 10:645-9. 2010
    ..Its antidepressant and recurrence prevention effects in bipolar disorder are under investigation, as is its possible role in major depressive disorder...
  18. ncbi Aripiprazole: pharmacology and evidence in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1001-9. 2007
    ..Aripiprazole constitutes an alternative mood-stabilizing pharmacologic avenue in bipolar disorder; its comparative efficacy in long-term recurrence prevention and bipolar depression is a future research vista...
  19. ncbi Residual anxiety symptoms in depressed primary care patients
    Roger S McIntyre
    University of Toronto, Toronto, Ontario, Canada
    J Psychiatr Pract 13:125-8. 2007
    ..The goal of this study was to characterize the burden of anxiety among residual depressive symptoms in naturalistic primary care settings...
  20. ncbi Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, ON, Canada
    Expert Opin Pharmacother 10:3061-75. 2009
    ..The data from the studies reviewed herein also indicate that quetiapine XR poses a low risk for extrapyramidal side effects in middle-aged and elderly individuals with major depressive disorder...
  21. ncbi Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:257-64. 2007
    ..A nascent explanatory theory regarding the pathophysiology of major depressive disorder posits that alterations in metabolic networks (e.g., insulin and glucocorticoid signaling) mediate allostasis...
  22. ncbi A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:673-86. 2009
    ..Asenapine is approved for bipolar disorder and schizophrenia. This was a 3-week, randomized, double-blind, placebo-controlled trial of asenapine for treating acute bipolar mania...
  23. ncbi Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada
    Arch Pediatr Adolesc Med 162:929-35. 2008
    ..To identify factors associated with incident cardiovascular events and metabolic disturbance in children and adolescents treated with antipsychotics...
  24. ncbi Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, ON, Canada
    Dialogues Clin Neurosci 10:203-13. 2008
    ..Subphenotyping bipolar disorder as a function of comorbidity and temporality of onset may provide an opportunity for refining disease pathophysiological models and developing innovative disease-modifying therapies...
  25. ncbi The relationship between childhood abuse and suicidality in adult bipolar disorder
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, University Health Network, Toronto, Ontario, Canada
    Violence Vict 23:361-72. 2008
    ..Anamnestic inquiry regarding childhood maltreatment is salient to risk assessment, illness management planning, preventative strategies, and treatment interventions in bipolar disorder...
  26. ncbi Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, 399 Bathurst St, Toronto, Ontario, Canada M5T 2S8, Canada
    J Clin Psychiatry 70:5-11. 2009
    ....
  27. ncbi Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Clin Psychiatry 70:240-6. 2009
    ..To describe the rate and trajectory of change in psychiatric polypharmacy during the past decade in children and adolescents treated for major depressive disorder...
  28. ncbi Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 22:443-53. 2008
    ..The neuroactive peptides, insulin, IGF-1 and incretins, or agents that facilitate their central effects (e.g. insulin-sensitizing agents), may constitute novel and possibly disease-modifying neurocognitive treatments...
  29. ncbi The hepatic safety profile of duloxetine: a review
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Metab Toxicol 4:281-5. 2008
    ..Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert...
  30. ncbi The effect of bipolar I disorder and major depressive disorder on workforce function
    R S McIntyre
    Department of Psychiatry, University of Toronto, ON, Canada
    Chronic Dis Can 28:84-91. 2008
    ..5 to 0.9). The data herein underscore the pernicious effect of BD on workforce function, and suggest that opportunistic screening for BD in all individuals utilizing employment assistance programs for depression might be warranted...
  31. ncbi Bipolar disorder and suicide: research synthesis and clinical translation
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Curr Psychiatry Rep 10:66-72. 2008
    ..A nascent database suggests that adjunctive psychosocial interventions may further reduce suicide risk in bipolar individuals...
  32. ncbi Asenapine versus olanzapine in acute mania: a double-blind extension study
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:815-26. 2009
    ..To assess the efficacy and tolerability of asenapine versus olanzapine in the extended treatment of bipolar mania...
  33. ncbi Comparing features of bipolar disorder to major depressive disorder in a tertiary mood disorders clinic
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:313-7. 2007
    ..We sought to describe features that distinguish individuals with bipolar disorder from major depressive disorder...
  34. ncbi Thiazolidinediones: from antioxidant to neurotherapeutic?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ont, Canada
    Med Hypotheses 69:773-7. 2007
    ..We propose that TZDs constitute a potentially novel disease-modifying treatment avenue for mood disorders...
  35. ncbi Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Affect Disord 100:S5-14. 2007
    ..This post-hoc analysis aims to extend our understanding of quetiapine's antimanic efficacy by evaluating its therapeutic effect across the full spectrum of manic symptoms...
  36. ncbi Problem gambling in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 102:27-34. 2007
    ..This investigation was undertaken to explore the prevalence and associated features of problem gambling amongst individuals with bipolar I disorder...
  37. ncbi Improving outcomes in depression: a focus on somatic symptoms
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Psychosom Res 60:279-82. 2006
    ..It is hypothesized that somatic symptom alleviation is a significant predictor of overall outcome in depressed primary care patients...
  38. ncbi Depression in the workforce: the intermediary effect of medical comorbidity
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, ON, Canada
    J Affect Disord 128:S29-36. 2011
    ..g., obesity, diabetes mellitus, cardiovascular disease). Emerging evidence indicates that the workforce dysfunction associated with depression is partially mediated by medical comorbidity...
  39. ncbi The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, ON, Canada
    Adv Ther 27:828-36. 2010
    ..To our knowledge, this is the first study reporting on the rate of metabolic syndrome in a Canadian clinical sample and exclusively evaluating asymptomatic individuals...
  40. ncbi When should you move beyond first-line therapy for depression?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Clin Psychiatry 71:16-20. 2010
    ..Taken together, practitioners are often faced with the critical question as to when to move beyond index therapy for treating depressive symptoms as part of MDD...
  41. ncbi The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:741-53. 2010
    ..Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome...
  42. ncbi Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale
    Roger S McIntyre
    University of Toronto, Toronto, Ont
    CMAJ 173:1327-34. 2005
    ..We evaluated a 7-item abbreviated version (HAMD-7) of the 17-item Hamilton Depression Rating Scale (HAMD-17) in a randomized controlled clinical trial of patients with major depressive disorder being cared for in primary care settings...
  43. ncbi The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, University Health Network, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Saf 5:157-68. 2006
    ..To synthesise results from investigations reporting on the effect of antidepressants on glucose-insulin homeostasis...
  44. ncbi Bipolar disorder and metabolic syndrome: an international perspective
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 126:366-87. 2010
    ....
  45. ncbi The effect of antidepressants on lipid homeostasis: a cardiac safety concern?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Drug Saf 5:523-37. 2006
    ..The authors sought to summarise and synthesise results from investigations which report on the effect of antidepressants on serum lipid homeostasis...
  46. ncbi Measurable outcomes in psychiatric disorders: remission as a marker of wellness
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Clin Ther 28:1882-91. 2006
    ..Collectively, they are associated with significant morbidity, mortality, and economic cost. Wellness is the optimal outcome in the management of chronic medical and psychiatric disorders...
  47. ncbi Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    J Affect Disord 126:358-65. 2010
    ..We report the results of long-term treatment with asenapine in patients with bipolar I disorder...
  48. ncbi Anxiety disorders and bipolar disorder: a review
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada
    Bipolar Disord 8:665-76. 2006
    ..Taken together, a compelling basis emerges for prioritizing the identification and management of anxiety symptomatology in the BPD population...
  49. ncbi Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Ontario
    Can J Psychiatry 51:274-80. 2006
    ..We further aimed to examine the likelihood of an association between obesity and MD, while controlling for the influence of sociodemographic variables...
  50. ncbi Calculated bioavailable testosterone levels and depression in middle-aged men
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Psychoneuroendocrinology 31:1029-35. 2006
    ..We sought to determine the relationship between physiologically active bioavailable testosterone (BT) and depressive symptoms in middle-aged men with and without major depressive disorder (MDD)...
  51. ncbi Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    Psychiatr Serv 57:1140-4. 2006
    ..This is the first cross-national population-based investigation exploring the prevalence and functional implications of comorbid general medical disorders in bipolar disorder...
  52. ncbi Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street Toronto, ON, M5T 2S8, Canada
    Expert Opin Pharmacother 7:1305-21. 2006
    ..Antidiabetic treatments, which maintain euglycaemia, hold promise as potent and clinically significant therapeutic interventions for several neuropsychiatric disorders...
  53. ncbi Asenapine: a review of acute and extension phase data in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    CNS Neurosci Ther 17:645-8. 2011
    ..Bipolar depression and recurrence prevention studies are required to fully characterize this novel agent's position in the treatment of bipolar disorder...
  54. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada
    Bipolar Disord 8:721-39. 2006
    ..The importance of comorbid psychiatric and medical conditions cannot be understated, and this update provides an expanded look at the prevalence, impact and management of comorbid conditions in patients with bipolar disorder...
  55. ncbi The antidepressant effects of risperidone and olanzapine in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Clin Pharmacol 11:e218-26. 2004
    ..To describe the antidepressant effectiveness of olanzapine and risperidone and compare their tolerability when employed adjunctively in bipolar I/II disorder...
  56. ncbi Overview of managing medical comorbidities in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e17. 2009
    ..Coordinated somatic and psychiatric treatment, weight-neutral or weight-reducing pharmaceuticals, and behavioral weight management programs may help lessen the burden of CVD in the mental health population...
  57. ncbi The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder
    C Y Yim
    Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
    Eur Psychiatry 27:223-8. 2012
    ..This sub-group post-hoc analysis preliminarily explores and examines the association between overweight/obesity and cognitive function in euthymic individuals with bipolar disorder...
  58. ncbi Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle
    V S Basile
    Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Ontario, Canada
    J Clin Psychiatry 62:45-66. 2001
    ....
  59. ncbi Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood and Anxiety Disorders Program, Center for Addiction and Mental Health, Clarke Site, Ontario, Canada
    Bipolar Disord 4:207-13. 2002
    ....
  60. ncbi Antipsychotic-induced weight gain: bipolar disorder and leptin
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 23:323-7. 2003
    ..05). The temporal association between weight increase and leptin changes does not support the notion that leptin is a primary promoter of antipsychotic-induced weight gain; however, a secondary perpetuating role cannot be ruled out...
  61. ncbi The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8
    Headache 46:973-82. 2006
    ..Opportunistic screening and surveillance for bipolar and comorbid migraine is warranted...
  62. ncbi Acute treatment of patients with bipolar mixed episodes
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 69:e10. 2008
    ..As more medications become available in the treatment of bipolar disorder, algorithms can help clinicians make the appropriate treatment choices by offering recommendations for sequencing agents...
  63. ncbi Comorbidity in bipolar disorder: a framework for rational treatment selection
    Roger S McIntyre
    Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S9, Canada
    Hum Psychopharmacol 19:369-86. 2004
    ..This schema should be further informed by the treatment data for comorbid and accessory conditions. The authors propose a schema to provide the impetus for further work in the area...
  64. ncbi Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 66:28-36. 2005
    ..This article reviews relevant adverse events attributable to the use of atypical antipsychotic agents, with particular consideration of the bipolar disorder population...
  65. ncbi Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia
    Roger S McIntyre
    Mood Disorders Psychopharmacology Clinic, Department of Psychiatry, University of Toronto, University Health Network, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T2S8
    Can J Psychiatry 48:689-94. 2003
    ..This investigation describes comparative NAP-induced weight gain in a prospective naturalistic cohort of persons with schizophrenia and related psychotic disorders...
  66. ncbi Managing weight gain in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e23. 2009
    ....
  67. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada
    Bipolar Disord 11:225-55. 2009
    ..Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder...
  68. ncbi Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
    Joanna K Soczynska
    University of Toronto, Institute of Medical Science, Toronto, ON, Canada
    Expert Opin Investig Drugs 17:827-43. 2008
    ..Mood disorders are associated with decrements in cognitive function, which are insufficiently treated with contemporary pharmacotherapies...
  69. ncbi Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited
    Roger S McIntyre
    Mood Disorders Program, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Ontario, Canada
    J Clin Psychiatry 63:15-20. 2002
    ..Most of their adverse effects can be avoided by slow titration toward the recommended doses. In contrast to carbamazepine and valproic acid, topiramate may be associated with weight loss...
  70. ncbi Bipolar disorder: a national health concern
    Roger S McIntyre
    University Health Network, Edith Cavell Wing 3D 003, 399 Bathurst St, M5T 2S8, Ontario, Canada
    CNS Spectr 9:6-15. 2004
    ....
  71. ncbi Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Ann Clin Psychiatry 17:83-93. 2005
    ..Preliminary investigations indicate that patients who suffer from BD with comorbid DM have a more severe course and outcome, lower quality of life, higher prevalence of medical comorbidity and higher cost of illness...
  72. ncbi Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Canada
    J Psychiatry Neurosci 30:178-86. 2005
    ..The available evidence suggests that a functional role for the cerebellum should be considered in future neuropsychiatric studies...
  73. ncbi The relationship between testosterone and sexual function in depressed and healthy men
    Sakina J Rizvi
    University Health Network, Department of Psychiatry, Toronto, Canada
    J Sex Med 7:816-25. 2010
    ..The objective of this study is to evaluate the effects of depression and low testosterone across various domains of sexual function...
  74. ncbi Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder
    Sidney H Kennedy
    University of Toronto, Ontario, Canada
    Can J Psychiatry 55:568-76. 2010
    ....
  75. ncbi Mechanisms of antipsychotic-induced weight gain
    R S McIntyre
    Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Ontario, Canada
    J Clin Psychiatry 62:23-9. 2001
    ..Research success in this area may invite novel prevention strategies and hint at potential mechanisms of antipsychotic drug action...
  76. ncbi An approach to managing depression. Defining and measuring outcomes
    Atul Khullar
    Department of Psychiatry, University of Alberta, Edmonton
    Can Fam Physician 50:1374-80. 2004
    ..The 7-item Hamilton Depression Rating Scale can assist clinicians in determining when full remission has occurred...
  77. ncbi The human cost of not achieving full remission in depression
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Psychiatry 49:10S-16S. 2004
    ....
  78. ncbi What to do if an initial antidepressant fails?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 49:449-57. 2003
    ..To provide family physicians with practical ways of managing depressed patients responding insufficiently to initial antidepressant treatment...
  79. ncbi Antipsychotic drugs and diabetes
    Roger S McIntyre
    CMAJ 168:673. 2003
  80. ncbi Reboxetine: a preliminary report on its use through the Special Access Program
    Sidney H Kennedy
    University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:418-22. 2002
    ..To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders...
  81. ncbi Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
    Eur Neuropsychopharmacol 15:573-85. 2005
    ..The primary efficacy outcome variable was change from baseline to Day 21 in Young Mania Rating Scale (YMRS) score...
  82. ncbi Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring
    Marie Josée Poulin
    Centre Hospitalier Affilie Universitaire De Quebec, Hopital de l Enfant Jesus, Quebec
    Can J Psychiatry 50:555-62. 2005
    ....
  83. ncbi Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care program
    Linda S Kahn
    State University of New York at Buffalo, USA
    Int J Psychiatry Med 38:13-29. 2008
    ....
  84. ncbi Editorial: sharpening the focus in mood disorders: from disease models to individualized measurement-based care
    Roger S McIntyre
    Ann Clin Psychiatry 19:213-4. 2007
  85. ncbi Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    J Clin Psychiatry 69:514-9. 2008
    ....
  86. ncbi Adverse events in children and adolescents treated with antipsychotic medications
    Jeanette M Jerrell
    Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, South Carolina 29203, USA
    Hum Psychopharmacol 23:283-90. 2008
    ..To report the odds of developing adverse events associated with antipsychotic treatment among children and adolescents...
  87. ncbi Validity of conclusions about quetiapine
    Roger S McIntyre
    Am J Health Syst Pharm 65:114-5; author reply 115-6. 2008
  88. ncbi Differentiating bipolar disorders from major depressive disorders: treatment implications
    David J Muzina
    Cleveland Clinic Neurological Institute, Psychiatry and Psychology, Cleveland, OH 44195, USA
    Ann Clin Psychiatry 19:305-12. 2007
    ..Bipolar disorder is a highly prevalent mood disorder, frequently misdiagnosed as unipolar major depressive disorder...
  89. ncbi Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 68:1480-91. 2007
    ..Efficacy and tolerability of aripiprazole for relapse prevention in bipolar I disorder was, therefore, evaluated for 100 weeks...
  90. ncbi Relationship between regional brain metabolism, illness severity and age in depressed subjects
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Psychiatry Res 155:203-10. 2007
    ..The age-dependent changes documented herein may influence the distinct clinical presentation and treatment response described in older-age depression...
  91. ncbi Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial
    Sidney H Kennedy
    University Health Network, Institute of Medical Science, University of Toronto, Department of Psychiatry, and Toronto General Hospital, 200 Elizabeth St, Eaton North Wing 8 222, Toronto, Ontario M5G 2C4, Canada
    Am J Psychiatry 164:778-88. 2007
    ..In this study, the authors report changes in fluorine-18-fluorodeoxyglucose PET in responders to CBT or venlafaxine during a randomized controlled trial...
  92. ncbi Sex differences in antidepressant response in a Canadian primary-care sample
    Sophie Grigoriadis
    J Clin Psychopharmacol 27:95-8. 2007
  93. ncbi Treating bipolar disorder. Evidence-based guidelines for family medicine
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 50:388-94. 2004
    ..To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office...
  94. ncbi Bipolar depression: trial-based insights to guide patient care
    David E Kemp
    Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio, USA
    Dialogues Clin Neurosci 10:181-92. 2008
    ..A pragmatic clinical approach is presented for management of the depressed phase of bipolar disorder...